<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35427481</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>399</Volume><Issue>10336</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.</ArticleTitle><Pagination><StartPage>1708</StartPage><EndPage>1717</EndPage><MedlinePgn>1708-1717</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(22)00313-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(22)00313-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Children are susceptible to severe or fatal enterovirus 71 (EV71) infections. We aimed to evaluate the efficacy, safety, and immunogenicity of EV71vac, an aluminium phosphate-adjuvanted inactivated EV71 vaccine in children aged 2-71 months.</AbstractText><AbstractText Label="METHODS">We did a randomised, double-blinded, placebo-controlled, phase 3 trial at five hospitals in Taiwan and two in Vietnam. Children aged 2-71 months were stratified by country and age, and randomly assigned (1:1) to receive two doses of EV71vac or placebo via intramuscular injection 56 days apart. Children aged 2-23 months received a third booster dose on day 366. The primary endpoint was the clinical efficacy of the total vaccinated cohort against EV71-associated diseases during the follow-up period, from 14 days after the second dose to when 15 cases of EV71 infections were confirmed in the per-protocol population. Our safety analysis included all participants who received at least one dose of EV71vac. This trial is registered with ClinicalTrials.gov, NCT03865238, and is complete.</AbstractText><AbstractText Label="FINDINGS">Between April 23 and Dec 25, 2019, of 3663 children assessed, 3061 were randomly assigned, of whom 3049 were vaccinated: 1521 children in the EV71vac group and 1528 in the placebo group. By May 20, 2021, our primary efficacy analysis included 2959 children, with 1476 children in the EV71vac group and 1483 children in the placebo group. The vaccine efficacy of EV71vac was 96&#xb7;8% (95% CI 85&#xb7;5-100) against EV71 associated diseases (p&lt;0&#xb7;0001). The percentage of participants who reported solicited adverse events were similar in both groups: 865 (56&#xb7;9%) in the EV71vac group and 852 (55&#xb7;8%) in the placebo group. Almost all reported solicited adverse events were mild and self-limited.</AbstractText><AbstractText Label="INTERPRETATION">EV71vac is safe, well-tolerated, and highly effective in preventing EV71 associated diseases in children aged 2-71 months.</AbstractText><AbstractText Label="FUNDING">Medigen Vaccine Biologics and A+ Industrial Innovative R&amp;D Program of the Ministry of Economic Affairs, Taiwan.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Trong Toan</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Cheng-Hsun</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Chang Gung Children's Hospital, Chang Gung University College of Medicine, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chien-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu City, Taiwan; Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Nan-Chang</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, MacKay Children's Hospital, Taipei City, Taiwan; Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Po-Yen</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Section of Infectious Disease, Department of Paediatrics, Taichung Veterans General Hospital, Taichung City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Thi Tuong Vy</ForeName><Initials>TTV</Initials><AffiliationInfo><Affiliation>Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Dang Ngan</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Centre for Disease Control of Tien Giang Province, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>An Han</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Centre for Disease Control of Dong Thap Province, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Van Luan</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Cai Lay Hospital, Tien Giang province, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>Thi Nguyet</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>Dong Thap Hospital, Dong Thap Province, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truong</LastName><ForeName>Huu Khanh</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Children's Hospital 1 in Ho Chi Minh City, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Trong Lan</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Thi Thanh Thao</ForeName><Initials>TTT</Initials><AffiliationInfo><Affiliation>Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Shin-Ru</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Research Centre for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan City, Taiwan; Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chung-Guei</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Research Centre for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan City, Taiwan; Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Yi-Jen</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Medigen Vaccine Biologics, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Erh-Fang</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Medigen Vaccine Biologics, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Stanley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medigen Vaccine Biologics, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>College of Science and Technology, Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>I-Chen</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Medigen Vaccine Biologics, Taipei City, Taiwan. Electronic address: kathytai@medigenvac.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Li-Min</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, National Taiwan University Children's Hospital, Taipei City, Taiwan. Electronic address: lmhuang@ntu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03865238</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2022 Apr 30;399(10336):1671-1673. doi: 10.1016/S0140-6736(22)00380-4</RefSource><PMID Version="1">35427482</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests CC, Y-JW, E-FH, and I-CT are employees of Medigen Vaccine Biologics Corporation and report grants from A+ Industrial Innovative R&amp;D Program of the Ministry of Economic Affairs, Taiwan, during the conduct of the study. TTN, C-HC, C-YL, N-CC, P-YC, TTVL, DNL, AHD, VLN, TNH, HKT, S-RS, C-GH, SC, and L-MH declare no other competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35427481</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)00313-0</ArticleId><ArticleId IdType="pii">S0140-6736(22)00313-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>